Powerful Insights. Better Outcomes. One Patient at a Time.

Comprehensive AI-driven solutions across pulmonary, cardiovascular, digestive, liver, endocrine, GU, women’s health, and emergency care pathways.

Schedule A Demo

Patient Management Software Suite for Incidental Findings and Cancer Screening Programs

Thynk Health unifies early detection, longitudinal tracking, and diagnostic follow-up for actionable findings across multiple organ systems.

ChatGPT Image Oct 7, 2025 at 04_42_40 PM.png

Explore Our Ecosystem

Our Vision for Healthcare

Thynk Health is a game-changer in patient management. With advanced AI (NLP and LLM) capabilities, we uncover hidden clinical insights, facilitate proactive tracking, and integrate AI-driven risk scores. Our mission is to revolutionize healthcare by ensuring no critical findings are overlooked.

Driven by our passion for innovation, we empower medical professionals to provide efficient, high-quality care. Thynk Health focuses on personalized patient journeys, automating follow-ups, and enhancing treatment outcomes through insightful analytics.

Schedule A Demo

News & Resources

LCS Program - ROI & Total Capture of Eligible Patients

The State of Lung Cancer Research Currently, 1 in 15 people in the U.S. can expect to receive a lung cancer diagnosis. Lung cancer kills almost twice as many women as breast cancer, and more than three times as many men as prostate cancer(1). In 2019, 142,670 Americans died of lung cancer – more than the next three cancers combined(2). Unfortunately, federal funding for lung cancer research per related death was just $1,680 compared to $24,846 for breast cancer, $12,644 for p

White Paper: Incidental Findings Management: Protecting Patients, Providers, & Healthcare Systems

Incidental findings : Results that arise that are outside the original purpose for which the test or procedure was conducted. Overview As imaging technology continues to advance, anomalies are increasingly more detectable, making incidental findings more commonplace. Recent systematic reviews (1) noted the mention of these findings in radiology reports is as high as 31 percent. However, proper communication and follow-up of incidental findings occur in about one in three occu

Build and Grow Your Lung Cancer Screening Management Program

Abstract In 2019, 142,670 Americans died of lung cancer— more than colorectal, breast and prostate cancer combined. Lung cancer remains the leading cause of cancer death. However, according to the American Lung Association (ALA), only 5.7 percent of the estimated 15 million eligible Americans at risk of developing lung cancer will undergo screening. Lung cancer screening should be considered a process, rather than a single test. Following the initial LDCT scan, a yearly scan